MS and Demyelinating Disorders

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

METEOROID is the first study to evaluate the efficacy and safety of satralizumab, an FDA-approved therapy for NMOSD, in patients with MOGAD.

Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.

A panel of experts in the treatment of patients with NMOSD discusses and offers insight into the vital aspects of diagnosis, disease management, and therapeutic strategy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

A group of experts in the care of patients with neurological conditions—Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath; Andrew Solomon, MD; Anne H. Cross, MD; Anthony Feinstein, MPhil, PhD, FRCP; Brian G. Weinshenker, MD, FRCP—shared their perspectives on hot topics of treatment and management in multiple sclerosis from the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting.

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, discussed the challenges in understanding and measuring fatigue in patients with multiple sclerosis.

As a recap from CMSC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

Clinical experts discuss differences and similarities between biosimilars and reference products.

Four advanced practice providers discuss biosimilars and how they can play an important role in healthcare.

In addition to increased relapse rates, use of fingolimod was associated with a 49% higher risk for disability accumulation in comparison with ocrelizumab.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

High and low doses of frexalimab resulted in reductions of new or enlarging T2 lesions and total T1 gadolinium-enhancing lesions over a 3-month period.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 23, 2023.

Dr Krieger, Dr Brandstadter, and Dr Lublin discuss the advances made in recognizing and managing multiple sclerosis over the last few decades and the challenges that remain.

Compared with placebo, inebilizumab-treated participants showed attenuated biomarker elevation during attacks and reduced biomarker levels over time in the absence of adjudicated attacks.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

A reduction in microglial activation was observed on the PET scans of most patients included. A phase 2 trial of the therapy was announced earlier this year and is still on track to begin sometime in the fall of 2023.

At CMSC 2023, the professor of psychiatry at the University of Toronto talked about cognitive behavioral therapy and mindfulness-based therapy that shows promise in alleviating fatigue in multiple sclerosis, offering potential treatment options. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and related disorders.